ZURICH (AFX) - Share prices are expected to open slightly lower tracking Wall Street's fall overnight but market sentiment might be lifted by strong earnings reported by SGS and Gerberit earlier this morning.
In pre-bourse trading, the Swiss Market Index was 27.20 points lower at 5,660.60.
Yesterday, the SMI closed 18.20 points higher at 5,687.80, and the Swiss Performance Index up 15.04 points at 4,235.99.
FORTHCOMING EVENTS
MONDAY
-Richemont Q1 trading statement (or any day next week)
COMPANY NEWS
-Roch's Avastin approved by EU for treatment of colorectal cancer
-Adecco names Jean-Manuel Bullukian president of Ajilon Worldwide
-Geberit FY sales up 35.8 pct on strong European growth
-Geberit FY sales 1.907 bln sfr vs. 1.404 bln
-Geberit expects substantially higher FY results
-SGS fy net 279 mln sfr vs 227 mln
-SGS says to make announcement regarding new CEO in coming weeks
-SGS FY DIV 12.0 sfr vS 9.0 sfr
-SGS still expects to meet 2005 eps target of 45 sfr
-SGS FY sales 2.885 bln sfr vs 2.454 bln
-SGS FY EBIT 378 mln sfr vs 293 mln
Sika FY sales rise 12.9 pct to 2.56 bln sfr on strong Asian, Lat Am growth
MARKET NEWS/SENTIMENT
-US blue chips closed at their lowest level in five weeks and the Nasdaq at its lowest point in eight weeks
-Consequently Swiss shares are expected to open low in early trade but might be lifted by company news, in particular strong earning results reported by SGS and Gerberit as well as an EU approval for Roche's cancer drug Avastin
ckj/at/jfr
For more information and to contact AFX: www.afxnews.com and www.afxpress.com
In pre-bourse trading, the Swiss Market Index was 27.20 points lower at 5,660.60.
Yesterday, the SMI closed 18.20 points higher at 5,687.80, and the Swiss Performance Index up 15.04 points at 4,235.99.
FORTHCOMING EVENTS
MONDAY
-Richemont Q1 trading statement (or any day next week)
COMPANY NEWS
-Roch's Avastin approved by EU for treatment of colorectal cancer
-Adecco names Jean-Manuel Bullukian president of Ajilon Worldwide
-Geberit FY sales up 35.8 pct on strong European growth
-Geberit FY sales 1.907 bln sfr vs. 1.404 bln
-Geberit expects substantially higher FY results
-SGS fy net 279 mln sfr vs 227 mln
-SGS says to make announcement regarding new CEO in coming weeks
-SGS FY DIV 12.0 sfr vS 9.0 sfr
-SGS still expects to meet 2005 eps target of 45 sfr
-SGS FY sales 2.885 bln sfr vs 2.454 bln
-SGS FY EBIT 378 mln sfr vs 293 mln
Sika FY sales rise 12.9 pct to 2.56 bln sfr on strong Asian, Lat Am growth
MARKET NEWS/SENTIMENT
-US blue chips closed at their lowest level in five weeks and the Nasdaq at its lowest point in eight weeks
-Consequently Swiss shares are expected to open low in early trade but might be lifted by company news, in particular strong earning results reported by SGS and Gerberit as well as an EU approval for Roche's cancer drug Avastin
ckj/at/jfr
For more information and to contact AFX: www.afxnews.com and www.afxpress.com